Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis

Launched by SHANGHAI PULMONARY HOSPITAL, SHANGHAI, CHINA · Sep 9, 2015

Keywords

ClinConnect Summary

The diagnosis and treatment of COPD and bronchiectasis together seems to be more complicated than the diagnosis and treatment of either condition alone. According to the GOLD，there are three treatments for patients with COPD in group C: ICS combined with LABA or LAMA alone or LABA combined with LAMA. However, it has not yet been demonstrated about which method is more effective for the patients with COPD in group C and bronchiectasis.

This study is designed as a prospective, randomized, case-control trial. Patients are divided into three groups, one group inhaled with ICS and LABA (Symbico...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients are suitable for inclusion in the study when they are 18 years or older diagnosed with COPD C group and bronchiectasis.
• Exclusion Criteria:
• • active tuberculosis
• • severe respiratory disease (such as Lung cancer, ARDS, pulmonary encephalopathy, respiratory failure)
• • uncontrollable diabetes
• • hypersensitivity to any components of ICS/LABA or LAMA.

Trial Officials